PANITUMUMAB
Healthy Participants
AstraZenecamonoclonal_antibodyPhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
4 Active assets in the Healthy Participants cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TACROLIMUS Mclean Hospital | Phase 1/2 | CC |
Doxycycline AstraZeneca | Phase 1 | CC |
REPAGLINIDE AstraZeneca | Phase 1 | CC |
Wellbutrin AstraZeneca | Phase 1 | CC |
Same molecule, other indications
PANITUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →